Key Takeaways
- • Fonds de solidarité FTQ, Canada's leading domestic life sciences investor ($100 million annually), committed an undisclosed amount to Paris-based AdBio Partners' third seed fund (€120 million / $193 million target) to establish AdBio's first North American office in Montreal.
- • AdBio Partners, spun from Advent Life Sciences, has raised over half its Fund III target and plans to deploy €2–3 million ($3.2–4.8 million) per investment across 3–4 Canadian companies, representing up to 20% of total fund deployment outside Europe.
- • AdBio's prior two funds (€67 million in 2017; €94 million in 2021) have backed 30 companies; Fund III co-investors include the European Investment Fund and French government-backed National Seed Fund 3, signaling institutional confidence in the strategy.
- • Montreal office leadership includes Mounia Azzi, former vice-president at adMare Bioinnovations, as partner, and Didier Leconte, formerly of Fonds de solidarité FTQ's life sciences division, as venture partner—both bringing local expertise and network access.
- • The initiative addresses Quebec's "trend of declining company creation" in biotech by filling a gap in early-stage company builder funding, leveraging the province's scientific talent and emerging entrepreneurial ecosystem.
Summary
Fonds de solidarité FTQ, Montreal-based and among Canada's largest domestic life sciences investors, has secured commitment from Paris-based early-stage venture fund AdBio Partners to establish its first office outside Europe in Quebec. The investment represents Fonds de solidarité FTQ's continued strategy to attract international capital to the province's biotech sector while addressing structural gaps in seed-stage funding for company formation.
AdBio Partners, which spun out of venture-capital giant Advent Life Sciences, is raising its third fund with a €120 million ($193 million) target, having already secured more than half that amount. The fund follows successful predecessors: a €67 million fund closed in 2017 and a €94 million fund in 2021, which collectively backed 30 biotech companies. Co-investors in Fund III include the European Investment Fund and the French government-backed National Seed Fund 3. Fonds de solidarité FTQ's commitment level remains undisclosed.
AdBio's Montreal office deployment marks a significant internationalization step. The firm plans to allocate up to 20% of Fund III—roughly €24 million maximum—to non-European investments, primarily concentrated in Quebec. Alain Huriez, AdBio chairman, outlined the Canadian thesis explicitly: backing three to four companies with initial cheques of €2–3 million ($3.2–4.8 million) each. Huriez cited Quebec's scientific talent base and identified a critical market gap: "a lack of early-stage company builder funds."
The Montreal office has hired two seasoned local operators to execute the strategy. Mounia Azzi, formerly vice-president at adMare Bioinnovations (a Canadian nonprofit providing lab space, funding, and support infrastructure for drug startups), has been elevated to partner to lead the office. Didier Leconte, who previously led life sciences investment activities for Fonds de solidarité FTQ itself, will serve as venture partner and board observer for portfolio companies. This combination of external credibility (Azzi's nonprofit sector experience) and insider knowledge (Leconte's prior institutional role) positions AdBio to navigate Quebec's biotech ecosystem effectively.
The announcement reflects a deliberate capital allocation decision by Quebec's flagship labour-sponsored fund to reverse documented headwinds in local biotech company formation. By anchoring a Paris-headquartered institutional manager with proven exit track records and European limited partner relationships, Fonds de solidarité FTQ appears to be leveraging foreign dry powder and operational expertise to revitalize early-stage deal flow.
AdBio Partners, which spun out of venture-capital giant Advent Life Sciences, is raising its third fund with a €120 million ($193 million) target, having already secured more than half that amount. The fund follows successful predecessors: a €67 million fund closed in 2017 and a €94 million fund in 2021, which collectively backed 30 biotech companies. Co-investors in Fund III include the European Investment Fund and the French government-backed National Seed Fund 3. Fonds de solidarité FTQ's commitment level remains undisclosed.
AdBio's Montreal office deployment marks a significant internationalization step. The firm plans to allocate up to 20% of Fund III—roughly €24 million maximum—to non-European investments, primarily concentrated in Quebec. Alain Huriez, AdBio chairman, outlined the Canadian thesis explicitly: backing three to four companies with initial cheques of €2–3 million ($3.2–4.8 million) each. Huriez cited Quebec's scientific talent base and identified a critical market gap: "a lack of early-stage company builder funds."
The Montreal office has hired two seasoned local operators to execute the strategy. Mounia Azzi, formerly vice-president at adMare Bioinnovations (a Canadian nonprofit providing lab space, funding, and support infrastructure for drug startups), has been elevated to partner to lead the office. Didier Leconte, who previously led life sciences investment activities for Fonds de solidarité FTQ itself, will serve as venture partner and board observer for portfolio companies. This combination of external credibility (Azzi's nonprofit sector experience) and insider knowledge (Leconte's prior institutional role) positions AdBio to navigate Quebec's biotech ecosystem effectively.
The announcement reflects a deliberate capital allocation decision by Quebec's flagship labour-sponsored fund to reverse documented headwinds in local biotech company formation. By anchoring a Paris-headquartered institutional manager with proven exit track records and European limited partner relationships, Fonds de solidarité FTQ appears to be leveraging foreign dry powder and operational expertise to revitalize early-stage deal flow.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.